STOCKWATCH
·
Pharmaceuticals
Quarterly Result15 Nov 2024, 01:12 pm

Kerala Ayurveda Reports 23% Revenue Growth in Q2 FY 24-25, Aims to Double Topline Growth

AI Summary

Kerala Ayurveda Ltd. (KAL) has reported a strong revenue growth in H1 FY 24-25, with consolidated revenue rising by 23% in Q2 and taking H1 revenue to a 19.2% increase over PY H1. The company's Q2 PAT is up 319 Lakhs vs. Q2 PY, taking H1 PAT to 411 Lakhs. KAL is on track to accelerate its growth trajectory, setting a target to double its topline growth to 25-30% in this fiscal year. The company is making significant investments in world-class talent, advanced technology, and expanded international reach to solidify its position as a global leader in the Ayurveda industry.

Key Highlights

  • Consolidated revenue in Q2 grew by 23% vs. previous year
  • H1 PAT at 6.7% vs.-0.58% H1 previous year
  • Plans to double the growth rate to a 25-30% topline increase in the coming year
  • Significant investments in world-class talent, advanced technology, and expanded international reach
  • Integration of Ayurvedagram Bali and the Om Vedic Singapore JV into KAL's consolidated structure
KERALAYUR
Pharmaceuticals
KERALA AYURVEDA LTD.

Price Impact